Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $509,605 | $3,280,323 | $2,834,695 | $10,953,856 |
| - Cash | $561,572 | $944,073 | $1,315,792 | $1,550,004 |
| + Debt | $467,731 | $239,309 | $442,588 | $23,030 |
| Enterprise Value | $415,764 | $2,575,559 | $1,961,491 | $9,426,882 |
| Revenue | $227,043 | $251,455 | $477,706 | $313,837 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Gross Profit | $188,494 | $197,450 | $273,490 | $184,147 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| EBITDA | -$484,394 | -$821,293 | -$2,059,659 | -$1,806,673 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |
| Net Income | -$547,029 | -$892,869 | -$2,104,929 | -$1,830,047 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| % Growth | 42.7% | 63.3% | 9.6% | – |
| Operating Cash Flow | -$319,585 | -$295,500 | -$252,198 | -$253,818 |
| Capital Expenditures | -$62,541 | -$40,801 | -$52,271 | -$56,521 |
| Free Cash Flow | -$382,126 | -$336,301 | -$304,469 | -$310,339 |